🔗 Share this article World Health Organization Issues Concern Over Acute Lack of Weight-Loss Medications Less than a tenth of individuals eligible to benefit from weight-loss injections like Wegovy can access them, caution the global health agency as it publishes its initial recommendations on the medications. With more than one billion people worldwide now obese, it is calling for increased and just access to this class of drugs. According to forecasts, more than two billion could be obese by 2030 unless action is taken. "The latest guidance recognises that obesity is a long-term condition that can be treated with thorough and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are major obstacles to broad availability to the jabs that can help people shift significant body mass, notes the body. Weight-Loss Drug Scarcity Even in the present most optimistic outlook, the supply of such drugs would only suffice for about 100 million people – under 10% of those who need them, as stated by the WHO. The advice urges countries and companies to expand access, via approaches like voluntary licensing. Exclusive production rights on the active ingredient – the core component of the drug Wegovy – is scheduled to end in several nations in 2026. The Way Weight-Loss Drugs Operate The injections replicate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so people reduce food intake. Individuals typically begin shedding pounds in the initial weeks of commencing the regular doses. Evidence suggests people may regain a significant portion a year later of stopping the medication, as their typical hunger come back. Being overweight or obese elevates your risk for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies. Excess weight impacts people in every country and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
Less than a tenth of individuals eligible to benefit from weight-loss injections like Wegovy can access them, caution the global health agency as it publishes its initial recommendations on the medications. With more than one billion people worldwide now obese, it is calling for increased and just access to this class of drugs. According to forecasts, more than two billion could be obese by 2030 unless action is taken. "The latest guidance recognises that obesity is a long-term condition that can be treated with thorough and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are major obstacles to broad availability to the jabs that can help people shift significant body mass, notes the body. Weight-Loss Drug Scarcity Even in the present most optimistic outlook, the supply of such drugs would only suffice for about 100 million people – under 10% of those who need them, as stated by the WHO. The advice urges countries and companies to expand access, via approaches like voluntary licensing. Exclusive production rights on the active ingredient – the core component of the drug Wegovy – is scheduled to end in several nations in 2026. The Way Weight-Loss Drugs Operate The injections replicate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so people reduce food intake. Individuals typically begin shedding pounds in the initial weeks of commencing the regular doses. Evidence suggests people may regain a significant portion a year later of stopping the medication, as their typical hunger come back. Being overweight or obese elevates your risk for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies. Excess weight impacts people in every country and was associated with 3.7 million deaths worldwide in 2024, per the health agency.